NCT07464756 2026-03-11
SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
Clinical Trials
19 trialsNCT07357532 2026-01-22
Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT07314372 2026-01-20
FAD-HCC-001
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Not yet recruiting
NCT07192848 2025-09-25
Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Phase 2 Not yet recruiting
NCT07031154 2025-06-22
A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer
The First Affiliated Hospital of Xiamen University
Phase 2 Not yet recruiting
NCT06881017 2025-03-18
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
China Medical University, China
Phase 2 Not yet recruiting
NCT06786312 2025-01-22
A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06771154 2025-01-13
A-CAPE
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT06764368 2025-01-08
Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors
Beijing Chest Hospital
Phase 2 Not yet recruiting
NCT06694324 2024-11-19
First-line Treatment of Advanced/unresectable DDLPS
Fudan University
Phase 2 Not yet recruiting
NCT06632522 2024-10-09
Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients .
Beijing Tsinghua Chang Gung Hospital
Phase 2 Not yet recruiting
NCT06546280 2024-08-09
A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation
Zhujiang Hospital
Phase 2 Not yet recruiting
NCT06537505 2024-08-05
A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors
Beidahuang Industry Group General Hospital
Phase 2 Not yet recruiting
NCT06482008 2024-07-01
HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06464614 2024-06-18
Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.
The First Affiliated Hospital of Henan University of Science and Technology
Phase 2 Not yet recruiting
NCT06385873 2024-05-13
RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06200233 2024-04-09
Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor
Samsung Medical Center
Phase 2 Not yet recruiting
NCT06081595 2023-10-13
Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment
Fudan University
Phase 2 Not yet recruiting
NCT05524974 2022-09-01
Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes
Fujian Medical University
Phase 2 Not yet recruiting